



**Extended Data Figure 7 | Validation of anti-PD-L1 and anti-CD8 antibodies through using *PD-L1* KO or *shCD8* cells.** **a**, Immunoblot (IB) analysis of whole cell lysates (WCL) derived from MDA-MB-231 cells depleted *PD-L1* through the CRISPR-Cas9 system. **b**, Immunofluorescence (IF) for MDA-MB-231 *PD-L1* WT and KO cells using the anti-PD-L1 antibody. The scale bar represents 50  $\mu$ m. **c**, **d**, Immunohistochemistry (IHC) for MDA-MB-231 *PD-L1* WT and KO cells from cultured on glass slides

(c) or implanted tumors (**d**) using the anti-PD-L1 antibody. The scale bar represents 50  $\mu$ m. **e**, **f**, IB analysis of WCL derived from HBP-ALL (**e**) or KE37 (**f**) cells stably expressing *shCD8* as well as *shScr* as a negative control using the anti-CD8 antibody. **g**, **h**, IHC for HBP-ALL (**g**) or KE37 (**h**) cell pellets stably expressing *shCD8* as well as *shScr* as a negative control using the anti-CD8 antibody. The scale bar represents 50  $\mu$ m.